Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | February 29, 2012 | March 02, 2012 |
| QuidelOrtho CorpQDEL · Entity 4986 | Director | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 29, 2012 · Filed March 02, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 229,617 |
Ending reported balance
After 2012-02-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2012-02-29 · Tax withholding · Disposed 15,954 · Balance 231,144 Row 2 · 2012-02-29 · Sale · Disposed 1,527 · Balance 229,617 |
QuidelOrtho Corp
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security | Direct | 15,532 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 15,532 · Balance 15,532 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. |
| Restricted Stock Units (Converted)SEC Table II · derivative / convertible security | Direct | 3,513 |
Reported balance
After 2026-06-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-25 · Grant · Acquired 3,513 · Balance 3,513 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4: 878 shares vested on June 25, 2026, 878 shares will vest on September 25, 2026, 878 shares will vest on December 25, 2026, and 879 shares will vest on March 25, 2027. |
| Restricted Stock Units (Premium)SEC Table II · derivative / convertible security | Direct | 1,053 |
Reported balance
After 2026-06-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-25 · Grant · Acquired 1,053 · Balance 1,053 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F2: The restricted stock units will vest on June 25, 2027.
F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.
F4: 878 shares vested on June 25, 2026, 878 shares will vest on September 25, 2026, 878 shares will vest on December 25, 2026, and 879 shares will vest on March 25, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
QUIDEL CORP /DE/
Report date May 27, 2022 · Filed June 01, 2022
Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 1
1 source rowRow 1 · 2022-05-27 · Disposition to issuer · Disposed 9,098 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-27 · Disposition to issuer · Disposed 1,137 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-27 · Disposition to issuer · Disposed 341 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-27 · Disposition to issuer · Disposed 356 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-27 · Disposition to issuer · Disposed 106 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-27 · Disposition to issuer · Disposed 555 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-27 · Disposition to issuer · Disposed 166 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
F2: Each restricted stock unit represents the right to receive one share of Quidel common stock.
F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2022 Filed Jun 1, 2022 21:47 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 341 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020512 · doc4.xml · derivative · entry 3 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341 Underlying: Common Stock · 341 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F3 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:47 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 1,137 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020512 · doc4.xml · derivative · entry 2 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,137 Underlying: Common Stock · 1,137 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F3 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:47 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 9,098 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020512 · doc4.xml · nonDerivative · entry 1 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,098 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. Read SEC document |
| May 18, 2022 Filed May 20, 2022 19:45 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031186 · doc4.xml · derivative · entry 2 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,624 shares Expires 2022-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. Read SEC document |
| May 18, 2022 Filed May 20, 2022 19:45 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031186 · doc4.xml · nonDerivative · entry 1 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:29 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Premium) · Derivative | 166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034696 · doc4.xml · derivative · entry 3 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166 Underlying: Common Stock · 166 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 18, 2022. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units vest on May 18, 2022. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:29 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Converted) · Derivative | 555 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034696 · doc4.xml · derivative · entry 2 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555 Underlying: Common Stock · 555 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 18, 2021. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 18, 2021. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:29 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Equity Grant) · Derivative | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034696 · doc4.xml · derivative · entry 1 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624 Underlying: Common Stock · 1,624 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 18, 2022. F2 · derivative.expiration_date: The restricted stock units vest on May 18, 2022. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:06 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units · Derivative | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032967 · doc4.xml · derivative · entry 2 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,040 shares Expires 2021-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:06 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032967 · doc4.xml · nonDerivative · entry 1 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:32 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | PurchaseCommon Stock | 3,500 | $288.12 | $1,008,403.90 |
DisclosureSEC source: 0001209191-20-045371 · doc4.xml · nonDerivative · entry 1 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,434 F1 · price: The weighted average purchase price for these transactions was $288.1154 per share, with a range of $288.1151 to $288.1157 per share. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:08 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units · Derivative | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030262 · doc4.xml · derivative · entry 2 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date. F3 · derivative.expiration_date: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:08 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030262 · doc4.xml · nonDerivative · entry 1 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document |
| May 12, 2020 Filed May 14, 2020 19:46 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Equity Grant) · Derivative | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029364 · doc4.xml · derivative · entry 3 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040 Underlying: Common Stock · 1,040 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F4 · derivative.exercise_date: The restricted stock units vest on May 12, 2021. F4 · derivative.expiration_date: The restricted stock units vest on May 12, 2021. Read SEC document |
| May 12, 2020 Filed May 14, 2020 19:46 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Premium) · Derivative | 106 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029364 · doc4.xml · derivative · entry 2 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106 Underlying: Common Stock · 106 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on May 12, 2021. F2 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on May 12, 2021. Read SEC document |
| May 12, 2020 Filed May 14, 2020 19:46 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Converted) · Derivative | 356 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029364 · doc4.xml · derivative · entry 1 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356 Underlying: Common Stock · 356 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F3 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 12, 2020. F2 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F3 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 12, 2020. Read SEC document |
| May 15, 2019 Filed May 16, 2019 19:31 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 834 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030638 · doc4.xml · nonDerivative · entry 1 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document |
| May 14, 2019 Filed May 16, 2019 19:31 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Equity Grant) · Derivative | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030638 · doc4.xml · derivative · entry 4 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 2,100 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F5 · derivative.exercise_date: The restricted stock units vest on May 14, 2020. F5 · derivative.expiration_date: The restricted stock units vest on May 14, 2020. Read SEC document |
| May 14, 2019 Filed May 16, 2019 19:31 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Premium) · Derivative | 341 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030638 · doc4.xml · derivative · entry 3 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341 Underlying: Common Stock · 341 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F5 · derivative.exercise_date: The restricted stock units vest on May 14, 2020. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F5 · derivative.expiration_date: The restricted stock units vest on May 14, 2020. Read SEC document |
| May 14, 2019 Filed May 16, 2019 19:31 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Converted) · Derivative | 1,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030638 · doc4.xml · derivative · entry 2 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,137 Underlying: Common Stock · 1,137 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 14, 2019. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 14, 2019. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 19:35 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units · Derivative | 417 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063340 · doc4.xml · derivative · entry 1 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417 Underlying: Common Stock · 417 shares Expires 2019-05-15 F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. Read SEC document |
| December 14, 2018 Filed Mar 22, 2019 20:16 UTC Amendment | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units · Derivative | 834 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021095 · doc4a.xml · derivative · entry 1 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 834 Underlying: Common Stock · 834 shares Expires 2019-05-15 F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,527 | $56.74 | $86,646.56 |
DisclosureSEC source: 0001179110-12-004070 · edgar.xml · nonDerivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,617 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 15,954 | $57.04 | $910,016.16 |
DisclosureSEC source: 0001179110-12-004070 · edgar.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,144 Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 71,500 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003261 · edgar.xml · derivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 Underlying: Common shares · 71,500 shares Expires 2022-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,834 on 02/17/2013, 23,833 on 02/17/2014, and 23,833 on 02/17/2015. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 39,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-003261 · edgar.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,098 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 06, 2012 Filed Feb 7, 2012 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,890 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · derivative · entry 11 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,890 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 06, 2012 Filed Feb 7, 2012 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,842 | $55.00 | $101,310.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 9 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,498 Read SEC document |
| February 06, 2012 Filed Feb 7, 2012 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,890 | $53.63 | $101,351.25 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 8 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 51,311 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · derivative · entry 10 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 51,311 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,200 | $55.02 | $121,044.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 7 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,450 Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,500 | $55.02 | $82,522.50 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 6 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,650 Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $55.01 | $5,501.25 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 5 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,150 Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,800 | $55.01 | $264,048.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 4 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,250 Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $55.01 | $11,001.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 3 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,050 Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 42,511 | $55.00 | $2,338,105.00 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,250 Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 51,311 | $53.63 | $2,751,552.38 |
DisclosureSEC source: 0001179110-12-002000 · edgar.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2011 Filed Nov 3, 2011 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 9,151 | $0.00 Strike: $53.87 | $0.00 |
DisclosureSEC source: 0001179110-11-014795 · edgar.xml · derivative · entry 11 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,151 Underlying: Common shares · 9,151 shares Expires 2013-07-14 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 01, 2011 Filed Nov 3, 2011 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 36,379 | $0.00 Strike: $53.87 | $0.00 |
DisclosureSEC source: 0001179110-11-014795 · edgar.xml · derivative · entry 10 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,379 Underlying: Common shares · 36,379 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 01, 2011 Filed Nov 3, 2011 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,640 | $0.00 Strike: $40.99 | $0.00 |
DisclosureSEC source: 0001179110-11-014795 · edgar.xml · derivative · entry 9 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 10,640 shares Expires 2013-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 01, 2011 Filed Nov 3, 2011 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 42,561 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001179110-11-014795 · edgar.xml · derivative · entry 8 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 42,561 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 01, 2011 Filed Nov 3, 2011 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,000 | $53.10 | $424,800.00 |
DisclosureSEC source: 0001179110-11-014795 · edgar.xml · nonDerivative · entry 7 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,450 Read SEC document |
| November 01, 2011 Filed Nov 3, 2011 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,286 | $53.24 | $121,708.93 |
DisclosureSEC source: 0001179110-11-014795 · edgar.xml · nonDerivative · entry 6 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,450 F1 · kind: Transaction made pursuant to a previously adopted plan complying with Rule 10b5-1(c). Read SEC document |
| November 01, 2011 Filed Nov 3, 2011 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,800 | $53.24 | $255,561.60 |
DisclosureSEC source: 0001179110-11-014795 · edgar.xml · nonDerivative · entry 5 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,736 F1 · kind: Transaction made pursuant to a previously adopted plan complying with Rule 10b5-1(c). Read SEC document |
| November 01, 2011 Filed Nov 3, 2011 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 45,530 | $53.87 | $2,452,701.10 |
DisclosureSEC source: 0001179110-11-014795 · edgar.xml · nonDerivative · entry 4 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,536 F1 · kind: Transaction made pursuant to a previously adopted plan complying with Rule 10b5-1(c). Read SEC document |
| November 01, 2011 Filed Nov 3, 2011 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,640 | $40.99 | $436,177.22 |
DisclosureSEC source: 0001179110-11-014795 · edgar.xml · nonDerivative · entry 3 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a previously adopted plan complying with Rule 10b5-1(c). Read SEC document |
| November 01, 2011 Filed Nov 3, 2011 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 42,561 | $41.03 | $1,746,350.18 |
DisclosureSEC source: 0001179110-11-014795 · edgar.xml · nonDerivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a previously adopted plan complying with Rule 10b5-1(c). Read SEC document |
| September 08, 2011 Filed Nov 3, 2011 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-014795 · edgar.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,865 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 767 | $47.98 | $36,802.96 |
DisclosureSEC source: 0001179110-11-003919 · edgar.xml · nonDerivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,865 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 13,363 | $47.64 | $636,613.32 |
DisclosureSEC source: 0001179110-11-003919 · edgar.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,632 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.